0001493152-26-020416
SEC filingThis 10-K/A amendment adds governance disclosures for Items 10-14 of Part III, including board composition, executive compensation structures, security ownership, related transactions, and auditor fees, without altering financial statements. It reflects compliance with delayed proxy statement rules under General Instruction G(3) for a non-accelerated filer.
This Amendment No. 1 to the 2025 10-K, filed April 30, 2026, amends the original March 12 filing by incorporating Items 10-14 of Part III. These cover directors and executive officers, executive compensation, security ownership of certain beneficial owners and management, related party transactions, and principal accountant fees and services, alongside updated exhibits. The filing explicitly confirms no updates to financial statements or subsequent events, leveraging General Instruction G(3) to omit these items initially due to the delayed proxy statement. As a non-accelerated filer and smaller reporting company listed on Nasdaq, Nephros avoids more stringent SOX 404(b) internal control audits, streamlining its reporting obligations while prioritizing governance transparency.
The amendment details board composition changes, emphasizing alignment of director expertise with Nephros' medtech focus. This refresh supports strategic oversight as the company advances its Nasdaq presence, ensuring directors contribute to operational and regulatory navigation without introducing new financial metrics.
Executive compensation structures are disclosed with linkages to revenue progress, restructuring pay to incentivize milestones. This approach motivates leadership amid signals of scaling operations, fostering accountability tied to business growth rather than fixed salaries alone.
A new policy shifts director pay toward equity incentives, promoting alignment with shareholder interests. Implemented to mature governance practices, it encourages long-term value creation for this emerging medtech firm.
Security ownership highlights key stakeholders, including affiliated directors, shaping governance dynamics. This concentration influences board decisions and strategic direction, common for smaller public companies balancing investor influence with independent oversight.
Overall, the amendment underscores Nephros' maturing governance framework as a Nasdaq-listed medtech player. By detailing pay structures linked to revenue signals and equity-based incentives, it signals operational momentum and regulatory adherence, all without financial restatements or new quantitative claims. This focus reassures investors of strengthened controls and leadership alignment in a phase of potential revenue scale.